AbolerIS Pharma

Foundation date

28/11/2019

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance and preserves useful immune responses in inflammatory, autoimmune and degenerative diseases.

Anti-CD45RC monoclonal antibody to deplete effector T cells and preserve regulatory and memory T cells.

IL-34 cytokine to induce tolerogenic macrophages/DCs and regulatory T cells.

Founded by a team with a long cutting-edge translational expertise in regulatory T cells and mechanisms of tolerance.

Upcoming events

Latest news

  • reMYND announces positive Phase 2a clinical trial results for treatment of mild-to-moderate Alzheimer’s disease

    Friday November 1st 2024

  • Can we protect nerve cells from dying?

    Friday November 1st 2024

  • Resistance in Candida auris, how to tackle a deadly fungus

    Wednesday October 30th 2024